The insG myodystrophy model generated in this work demonstrates the phenotype seen in mild to severe DMD cases; the mutation is homologous to the most common dystrophin mutation found in the human population and thus can be used for the development and testing of both pharmaceutical agents and gene therapy designed for alternative splicing regulation. Here, DMD is linked to Duchenne muscular dystrophy.